Mesalazine controlled release - Ferring

Drug Profile

Mesalazine controlled release - Ferring

Alternative Names: Mesalamine granules - Ferring; Pentasa; Pentasa® controlled release 500mg tablets; Pentasa® prolonged release granules 1g/2g/4g; Pentasa® Sachet; PS-QD

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer Ferring Pharmaceuticals; Kyorin Pharmaceutical; Shire US
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 19 Sep 2018 Ferring Pharmaceuticals completes a phase III trial for Ulcerative Colitis in USA, Bulgaria, Canada, Latvia, Hungary, Mexico, Poland, Russia, Switzerland, Serbia, Ukraine and Belgium (PO, once-daily granules 2g ) (NCT02522780) (EudraCT2015-002558-11)
  • 03 Apr 2018 Ferring Pharmaceuticals completes a phase III trial for Ulcerative colitis in USA, Belgium, Bulgaria, Latvia, Mexico, Hungary, Canada, Poland, Russia, Switzerland, Ukraine and Serbia (NCT02522767)
  • 25 Jul 2017 Ferring Pharmaceuticals completes a phase III trial in Ulcerative colitis in China (Rectal) (NCT02368717)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top